Jaunt

Tag #sjia

NextGen 2024: Weaning meds when disease is controlled Session Part 2

NextGen 2024: Weaning meds when disease is controlled Session Part 1

NextGen 2024: Genetics in SJIA Session Part 3

NextGen 2024: Genetics in SJIA Session Part 2

NextGen 2024: Genetics in SJIA Session Part 1

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 2

NextGen 2024: Monitoring &Treating Lung Disease in SJIA Session Part 1

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 5

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 4

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 3

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 2

NextGen 2024: Bone Marrow Transplantation (BMT) Session Part 1

$NextGen 2024: Refractory SJIA & MAS Session Part 8$

$NextGen 2024: Refractory SJIA & MAS Session Part 7$

$NextGen 2024: Refractory SJIA & MAS Session Part 6$

$NextGen 2024: Refractory SJIA & MAS Session Part 5$

$NextGen 2024: Refractory SJIA & MAS Session Part 4$

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 2

NextGen 2024: Unmet Needs & Clinical Trial Challenges Session Part 1

$NextGen 2024: Refractory SJIA & MAS Session Part 3$

$NextGen 2024: Refractory SJIA & MAS Session Part 2$

$NextGen 2024: Refractory SJIA & MAS Session Part 1$

IL-18 testing in the diagnosis and management of Still’s disease:
Game-changer or Red Herring?

Clinical significance of serum IL-18 levels
for the diagnosis and monitoring of disease activity

Current treatments in macrophage activation syndrome - METAPHOR projec

This website uses cookies to improve your experience. By using this site, you consent to the use of cookies.